Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

PURPOSE: Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for...

Descripción completa

Detalles Bibliográficos
Autores principales: Garon, Edward B., Hellmann, Matthew D., Rizvi, Naiyer A., Carcereny, Enric, Leighl, Natasha B., Ahn, Myung-Ju, Eder, Joseph Paul, Balmanoukian, Ani S., Aggarwal, Charu, Horn, Leora, Patnaik, Amita, Gubens, Matthew, Ramalingam, Suresh S., Felip, Enriqueta, Goldman, Jonathan W., Scalzo, Cathie, Jensen, Erin, Kush, Debra A., Hui, Rina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2019
Materias:
RAPID COMMUNICATION
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768611/
https://www.ncbi.nlm.nih.gov/pubmed/31154919
http://dx.doi.org/10.1200/JCO.19.00934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768611/
https://www.ncbi.nlm.nih.gov/pubmed/31154919
http://dx.doi.org/10.1200/JCO.19.00934

Ejemplares similares